Cannabis Science Global Consortium

Cannabis Science Global Consortium

The CBIS Global Consortium provides the us with a framework to cooperate and collaborate with...

  • The objective of the consortium is to harness the collective expertise of our global partners to investigate the use of Cannabinoids for the treatment of a variety of indications, including cancers, neurological conditions, pain management, the treatment of HIV and AIDS, and epilepsy.

    The Cannabis Science Global Consortium will link universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside. The CBIS Global Consortium will also enable the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.

    There are three primary elements in Cannabis Science's drug development program:

    Defining the effectiveness and specificity of cannabinoids being tested;

    Identifying and testing drug delivery mechanisms; and

    Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in our randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions

  • Category
  • Created
    Wednesday, 23 January 2019
  • Group admin
    Raymond C. Dabney

Cannabis Science Economic Development Program

Cannabis Science Economic Development Plan

Cannabis Science Share Structure Updates

CBIS Share Structure Updates

Cannabis Science Updates

CBIS Updates

Transfer Agent

Securities Transfer Corp.

STC is regulated by the Securities and Exchange Commission

2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101

Become an iCannabinoid Ambassador


Observational Studies


Activity Stream

Raymond C. Dabney Raymond C. Dabney This is exactly why I wrote this statement.

We will probably put out the July 1, 2020 Edition after the Fourth...
Show more

Dale Leister Not sure how to see your post, the last thing I saw from you was two months ago. I’m not trying to push or be sarcastic I’m just trying to find out... Show more yesterday
Raymond C. Dabney I think if you click my profile name or anyone's name in the system you can see all the posts they've ever written, that is not deleted. It is... Show more Loading content, please wait. 14 hours 44 minutes ago
Tim W. H. Raymond, one of the strong points of our company website is the shareholder 'free speech' aspect.
Unfortunately, this day and time internet dialog...
Show more
10 hours 35 minutes ago



Sorry, we currently have no events.
View All Events